DUBLIN — (BUSINESS WIRE) — December 27, 2017 — The "3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035" report has been added to Research and Markets' offering.
The 3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035' report provides a comprehensive study on the current market landscape of the 3D bioprinting industry, featuring an elaborate discussion on the future potential of this evolving market. The field has seen the emergence of many new players in the past few years; in fact, several well-known players of the 3D printing industry have broadened their focus to launch new initiatives specific to 3D bioprinting.
3D printing has garnered significant attention within the healthcare industry. The concept of 3D bioprinting was conceived in the late 1990s; since then, various industry stakeholders and academicians have undertaken several initiatives in order to further develop / improve this technology for a variety of applications. Organovo was the first company to enter the 3D bioprinting space by printing functional blood vessels in 2010. The company now offers 3D printed kidney and liver tissue models. There have been a number of other notable attempts to create fully functional 3D bioprinted tissues.
The current applications of 3D bioprinted products cater to various requirements within the pharmaceutical industry for clinical testing of therapeutic drugs. Owing to the evident interspecies differences, drug candidates that are shown to be efficacious in animal models often fail in humans. For such purposes, 3D bioprinting can be used to develop more accurate, human specific disease models. Further, there is a severe unmet need when it comes to organ transplants. Therefore, the ability to synthetically create organs for transplantation purposes is expected to generate a lot of interest amongst pharmaceutical / biotechnology players in the coming years.
The current market landscape of 3D bioprinting is characterized by the presence of nearly equal number of industry and non-industry players, featuring a number of startups and university spin-offs. Although there are several 3D bioprinting technologies already available, active efforts are being made to add to the intellectual property portfolio. The field has witnessed growing partnering activity and has also managed to capture the interest of both public and private sector investors. Despite certain challenges, several technical advancements and high unmet need of current patients waiting for organ transplants is anticipated to significantly drive future growth.
Key Topics Covered:
1. Preface
- Scope of the Report
- Research Methodology
- Chapter Outlines
2. Executive Summary
3. Introduction
- 3D Printing Technology
- 3D Bioprinting: Printing of Living Cells, Tissues and Organs
4. Market Landscape
- 3D Bioprinting: Overall Market Landscape
- 3D Bioprinters by Non-Industry Players
- 3D Bioprinted Products by Non-Industry Players
5. Company Profiles
- 3Dynamic Systems
- Aspect Biosystems
- Allevi (formerly BioBots)
- BioDan Group
- CELLINK
- EnvisionTEC
- GeSiM
- MEDPRIN BIOTECH
- microdrop Technologies
- MicroFab Technologies
- Nano3D Biosciences
- Organovo
- Qingdao Unique Products Develop
- regenHU
- SunP Biotech International
6. Recent Collaborations and Funding
- Partnership Models
- 3D Bioprinting: Recent Collaborations
- Venture Capital Interest
- Types of Funding
- 3D Bioprinting: Funding Instances
